Go Deep
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,543 | -3.2 | 4.67 | 0.52 | 229.51 |
| Oct 2026 | 19,682 | -3.1 | 4.51 | 0.52 | 221.23 |
| Oct 2026 | 19,355 | -3.3 | 4.79 | 0.52 | 235.03 |
| Oct 2026 | 19,595 | -3.0 | 4.40 | 0.52 | 215.00 |
| Oct 2026 | 19,540 | -3.0 | 4.46 | 0.52 | 218.08 |
| Oct 2026 | 19,431 | -3.1 | 4.57 | 0.52 | 223.77 |
| Oct 2026 | 19,449 | -3.1 | 4.55 | 0.52 | 222.27 |
| Oct 2026 | 19,413 | -3.1 | 4.59 | 0.52 | 223.71 |
Sana Biotechnology, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -63,635,000.0 | -47,210,000.0 | -58,825,000.0 | -42,152,000.0 |
| EPS | -0.2 | -0.2 | -0.2 | -0.2 |
Sana Biotechnology, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -244,166,000.0 | -266,759,000.0 | -283,255,000.0 | -269,476,000.0 | — |
| EPS | -1.0 | -1.2 | -1.5 | -1.4 | — |
Sana Biotechnology, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 416,890,000.0 | 501,020,000.0 | 565,299,000.0 | 822,720,000.0 | — |
| Total Liabilities | 256,006,000.0 | 250,516,000.0 | 277,793,000.0 | 323,405,000.0 | — |
| Total Equity | 160,884,000.0 | 250,504,000.0 | 287,506,000.0 | 499,315,000.0 | — |
Owes vs Owns
Sana Biotechnology, Inc. owed $0.64 for every $1 it owned in Jun 2026, up from $0.39 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.64× | 0.61× | 0.50× | 0.49× | 0.39× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sana Biotechnology, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 33.2%Fixed assets (tangible) 15.6%Intangible assets 47.9%Other assets 3.2%
How it's funded — Dec 2025
Short-term debt 3.6%Long-term debt 15.3%Other liabilities 42.1%Shareholders' equity 38.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 138.4 | 152.5 | 205.2 | 424.0 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 65.2 | 135.3 | 145.6 | 159.4 |
| Intangible assets | 199.8 | 199.8 | 199.8 | 199.8 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 10.1 |
| Other assets | 13.5 | 13.4 | 14.7 | 29.5 |
| Liabilities & equity | ||||
| Short-term debt | 14.9 | 12.5 | 13.2 | 12.4 |
| Long-term debt | 63.9 | 81.7 | 90.9 | 95.9 |
| Payables | 1.7 | 5.2 | 4.1 | 2.9 |
| Other liabilities | 175.5 | 151.1 | 169.6 | 212.3 |
| Shareholders' equity | 160.9 | 250.5 | 287.5 | 499.3 |
| Net tangible assets | -38.9 | 50.7 | 87.7 | 299.5 |
Sana Biotechnology, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -143,828,000.0 | -223,153,000.0 | -253,582,000.0 | -290,050,000.0 | — |
| Investing Activities | -40,238,000.0 | 17,453,000.0 | 172,012,000.0 | 210,562,000.0 | — |
| Financing Activities | 128,733,000.0 | 199,749,000.0 | 31,646,000.0 | 4,913,000.0 | — |